Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/25/26
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-TermZacks Investment Research • 03/19/26
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-TermZacks Investment Research • 03/18/26
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian CancerGlobeNewsWire • 03/17/26
Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise GrowthSeeking Alpha • 02/24/26
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 02/24/26
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened ExecutionGlobeNewsWire • 02/23/26
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the TestGlobeNewsWire • 02/19/26
Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/18/26
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026GlobeNewsWire • 02/16/26
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial GuidanceGlobeNewsWire • 01/12/26
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast HealthGlobeNewsWire • 11/25/25
Myriad (MYGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/04/25
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid ExecutionGlobeNewsWire • 11/03/25